Research location
Santiago de Compostela
Galicia, Spain
Advertisement
Research activity in Santiago de Compostela
Galicia, SpainCureCurrent currently publishes aggregate city-level research activity for this location: 68 trials and 68 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Santiago de Compostela
68 linked trials · page 1 of 2Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLCNCT07246863 · 2025-10-07 · 1 site observation
RECRUITING
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLCNCT07098988 · 2025-08-01 · 1 site observation
RECRUITING
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 · 2025-07-25 · 1 site observation
RECRUITING
Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.NCT06724159 · 2024-12-13 · 1 site observation
RECRUITING
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor AntagonistsNCT06033950 · 2024-08-20 · 1 site observation
RECRUITING
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)NCT06024746 · 2024-07-09 · 1 site observation
RECRUITING
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]NCT06422143 · 2024-06-10 · 1 site observation
RECRUITING
Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.NCT07717268 · 2024-05-16 · 1 site observation
RECRUITING
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure PatientsNCT06008197 · 2024-01-17 · 1 site observation
RECRUITING
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.NCT05918302 · 2023-10-27 · 1 site observation
RECRUITING
REACTION-VAD Trial: Remote Exercise Training Via Telemedicine in Patients With Long-Term Ventricular Assist DevicesNCT07611188 · 2026-05-01 · 1 site observation
NOT_YET_RECRUITING
Prostate Cancer Awareness and Initiative for Screening in the European UnionNCT06424275 · 2024-06-01 · 1 site observation
ENROLLING_BY_INVITATION
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)NCT06117774 · 2024-02-20 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary FibrosisNCT06025578 · 2023-10-25 · 1 site observation
ACTIVE_NOT_RECRUITING
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)NCT05649722 · 2023-05-11 · 1 site observation
COMPLETED
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionNCT05325866 · 2022-09-23 · 1 site observation
TERMINATED
A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 InsertionNCT05419700 · 2022-08-05 · 1 site observation
COMPLETED
A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line TreatmentNCT04933695 · 2022-01-28 · 1 site observation
TERMINATED
Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast CancerNCT04874025 · 2021-07-31 · 1 site observation
COMPLETED
A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.NCT04742413 · 2020-12-29 · 1 site observation
TERMINATED
Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positiveNCT03790397 · 2019-02-26 · 1 site observation
COMPLETED
Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-ANCT03447769 · 2018-03-16 · 1 site observation
TERMINATED
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection FractionNCT02929329 · 2017-01-06 · 1 site observation
COMPLETED
randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart FailureNCT02900378 · 2016-12-20 · 1 site observation
COMPLETED
Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.NCT02919059 · 2016-12-13 · 1 site observation
UNKNOWN
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCNCT02941926 · 2016-11-30 · 1 site observation
COMPLETED
European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT02495974 · 2015-09-08 · 1 site observation
COMPLETED
Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)NCT02435680 · 2015-08-10 · 1 site observation
COMPLETED
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.NCT02437318 · 2015-07-23 · 1 site observation
COMPLETED
Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid ArthritisNCT02638259 · 2015-02-21 · 1 site observation
COMPLETED
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerNCT02278120 · 2014-11-20 · 1 site observation
COMPLETED
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection FractionNCT02226120 · 2014-10-16 · 1 site observation
COMPLETED
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection FractionNCT01920711 · 2014-07-18 · 1 site observation
COMPLETED
Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line MonochemotherapyNCT02403869 · 2014-03-12 · 1 site observation
COMPLETED
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) PatientsNCT02064868 · 2014-01-31 · 1 site observation
TERMINATED
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast CancerNCT01958021 · 2013-12-17 · 1 site observation
COMPLETED
PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast CancerNCT01973660 · 2013-10-01 · 1 site observation
COMPLETED
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to OlmesartanNCT01876368 · 2013-09-01 · 1 site observation
COMPLETED
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and CrizotinibNCT01828112 · 2013-06-28 · 1 site observation
COMPLETED
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORiNCT01633060 · 2012-10-03 · 1 site observation
TERMINATED
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast CancerNCT01617668 · 2012-08-01 · 1 site observation
COMPLETED
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100NCT01605227 · 2012-07-01 · 1 site observation
COMPLETED
Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsNCT01495702 · 2011-12-01 · 1 site observation
COMPLETED
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate CancerNCT01322490 · 2011-11-28 · 1 site observation
COMPLETED
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)NCT01350804 · 2011-09-01 · 1 site observation
COMPLETED
An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic HypertensionNCT01281306 · 2011-01-01 · 1 site observation
COMPLETED
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple SclerosisNCT01201356 · 2010-09-13 · 1 site observation
COMPLETED
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes MellitusNCT01171976 · 2010-09-01 · 1 site observation
COMPLETED
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With TrastuzumabNCT01271920 · 2010-09-01 · 1 site observation
COMPLETED
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious UveitisNCT01090310 · 2010-08-01 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.